Blood and Plasma Components Market - A Global and Regional Analysis

Focus on Product, Application, End User and Region - Analysis and Forecast, 2021-2031

Published Year:
SKU:BHL1182SA

$5250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Market Report Coverage

Blood and Plasma Components Market
Forecast Period: 2021-2031
CAGR During Forecast Period: 4.90%

Blood and Plasma Components Market

Base Year

2020

Market Size in 2021

$41.18 Billion

Forecast Period

2021-2031

Value Projection and Estimation by 2031

$66.47 Billion

CAGR During Forecast Period

4.90%

Number of Tables

28

Number of Pages

228

Number of Figures

158

Market Segmentation

•    Product - Transfusion Products and Plasma-Derived Products

•    Application - Hemtology, Solid Tumor Management, and Others

•    End User - Hospitals and Specialty Clinics, Research Institutions, Diagnostics Laboratories, and Other End Users

Regional Segmentation

•    North America - U.S. and Canada

•    Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe

•    Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

•    Rest-of-the-World

Market Growth Drivers

•    Global Increase in Patients with Blood Disorders

•    Increase in Trauma Patients and Chronic Illnesses

•    Rise in Number of Product Launches and Approval

Market Challenges

•    Risk of Transfusion Transmitted Infectious Diseases and Adverse Reaction Associated with Blood Transfusion

•    Long Duration of Manufacturing Process and Strict Regulatory Guidelines

Market Opportunities

•    Increase in Adoption of Business Expansion Strategies in the Market

Key Companies Profiled

CSL Limited, Grifols, S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, GC Pharma, Octapharma AG,  Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., American Red Cross, Versiti, Inc., Blood Centers of America, Carter BloodCare, Memorial Blood Centers

Key Questions Answered in this Report:

How did the COVID-19 pandemic impact the global blood and plasma components ecosystem?

•    How are blood and plasma components revolutionizing the hematology and solid tumor management landscape?
•    What are the major market drivers, challenges, and opportunities in the global blood and plasma components market?
•    What are the underlying structures resulting in the emerging trends within the global blood and plasma components market?
•    How did the COVID-19 pandemic impact the global blood and plasma components ecosystem?
•    What are the key development strategies that are being implemented by major players in order to sustain themselves in the competitive market?
•    What are the key regulatory implications in developed and developing regions pertaining to the use of blood and plasma components?
•    What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market? 
•    What will be the growth rate of the global blood and plasma components market during the forecast period?
•    How is each segment of the market expected to grow during the forecast period 2021-2031, and what revenue is anticipated to be generated by each of the segments? Following are the segments:
        o    Product (Transfusion Market and Plasma-Derived Products)
        o    Application (Hematology, Solid Tumor Management, and Others)
        o    End Users (Hospitals and Specialty Clinics, Research Institutions, Diagnostics Laboratories, and Other End Users)
        o    Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
•    What are the growth opportunities for the blood and plasma components companies in the region of their operation?
•    Who are the leading players with significant offerings in the global blood and plasma components market? 
•    Which companies are anticipated to be highly disruptive in the future, and why?

Report Summary

The market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031.

Market Overview

The global blood and plasma components market is expected to witness minimal growth, attributing to the rising burden of primary immunodeficiency diseases such as hemophilia A, von Willebrand disease (vWD), and secondary immunodeficiency diseases. Further, the increasing burden of cancer, hematologic malignancies, and organ transplantation is also contributing to the growth of the market. An increase in research and development into the use of plasma components for the treatment of neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) is also promoting the growth of the market. Moreover, initiatives taken by the major players in the global blood and plasma components market to expand and launch more blood and plasma collection centers across the world in order to fulfill the supply of blood and plasma components are the major factors that are expected to fuel the growth of the market. The market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.

Blood and Plasma Components Market

Competitive Landscape

The global blood and plasma components market comprises well-established companies as well as a few newly emerging companies. Several companies in the global blood and plasma components market are attempting to expand their presence in the market by undertaking business expansion activities such as launching new blood and plasma collection centers at new locations. Moreover, the companies are constantly working on research and development to expand the indications of already present plasma-derived products in the market. The key market players of the global blood and plasma components market witnessed majorly business expansion, product approvals, and synergistic activities in the market over the period January 2018-January 2022. The inclination of companies toward product approvals, synergistic activities, and business expansion activities suggests that companies are constantly working to explore the potential of blood and plasma components for new areas of applications and offer products to fulfill the increased demand for blood and plasma components.

Table of Contents

Download this TOC

Request a Sample

1.1    Product Definition
         1.1.1    Inclusion and Exclusion Criteria
1.2    Market Scope
         1.2.1    Scope of the Study
         1.2.2    Key Questions Answered in the Report
1.3    Research Methodology
         1.3.1    Global Blood and Plasma Components Market: Research Methodology
         1.3.2    Data Sources
                     1.3.2.1    Primary Data Sources
                     1.3.2.2    Secondary Data Sources
         1.3.3    Market Estimation Model
         1.3.4    Criteria for Company Profiling
1.4    Market Overview
         1.4.1    Red Blood Cells
         1.4.2    Platelets
         1.4.3    Plasma
         1.4.4    Granulocytes
1.5    Historical Trends in the Use of Blood Components
1.6    Use of Blood Components
1.7    Market Footprint and Future Potential, $Million, 2020-2031

2.1    Overview
2.2    Regulatory Framework
         2.2.1    Regulatory Framework in the U.S.
         2.2.2    Regulatory Framework in the European Union
         2.2.3    Regulatory Framework in Asia-Pacific
                     2.2.3.1    China
                     2.2.3.2    Japan
2.3    Supply Chain Analysis
2.4    Impact of COVID-19 on Global Blood and Plasma Components Market

3.1    Overview
3.2    Impact Analysis
3.3    Market Drivers
         3.3.1    Global Increase in Patients with Blood Disorders
         3.3.2    Increase in Trauma Patients and Chronic Illnesses
         3.3.3    Rise in number of Product Launches and Approvals
3.4    Market Restraints
         3.4.1    Risk of Transfusion Transmitted Infectious Diseases and Adverse Reaction Associated with Blood Transfusion
         3.4.2    Long Duration of Manufacturing Process and Strict Regulatory Guidelines
3.5    Market Opportunities
         3.5.1    Increase in Adoption of Business Expansion Strategies in the Market

4.1    Overview
4.2    Corporate Strategies
         4.2.1    Mergers and Acquisitions
         4.2.2    Synergistic Activities
         4.2.3    Business Expansion, Funding, and Reimbursement Activities
4.3    Business Strategies
         4.3.1    Product Launches
         4.3.2    Product Approvals
4.4    Market Share Analysis, by Company (2020)
4.5    Growth-Share Analysis

5.1    Overview
5.2    Transfusion Market
         5.2.1    Packed Red Blood Cells
         5.2.2    Platelet Products
         5.2.3    Frozen Plasma
5.3    Plasma-Derived Products
         5.3.1    Immunoglobulins
                     5.3.1.1    Intravenous Immunoglobulins
                     5.3.1.2    Subcutaneous Immunoglobulins
                     5.3.1.3    Other Immunoglobulins
         5.3.2    Coagulation Factor Concentrates
                     5.3.2.1    Coagulation Factor VIII Concentrate
                     5.3.2.2    Coagulation Factor IX Concentrate
                     5.3.2.3    von Willebrand Factor (vWF)
                     5.3.2.4    Prothrombin Complex Concentrates
                     5.3.2.5    Coagulation Factor XIII Concentrate
         5.3.3    Albumins
         5.3.4    Proteinase Inhibitors
         5.3.5    Other Blood Derivatives

6.1    Overview
6.2    Hematology
         6.2.1    Hemoglobinopathy
                     6.2.1.1    Thalassemia
                     6.2.1.2    Sickle Cell Disease
                     6.2.1.3    Platelet Refractoriness
         6.2.2    Hematologic Malignancies Management
         6.2.3    Coagulopathy
                     6.2.3.1    Hemophilia
                     6.2.3.2    von Willebrand Disease
                     6.2.3.3    Thrombosis
                     6.2.3.4    Thrombocytopenia
6.3    Solid Tumor Management
6.4    Others
6.5    Emerging Areas of Application

7.1    Overview
7.2    Hospitals and Specialty Clinics
7.3    Research Institutions
7.4    Diagnostic Laboratories
7.5    Other End Users

8.1    Overview
8.2    North America
         8.2.1    U.S.
         8.2.2    Canada
8.3    Europe
         8.3.1    Germany
         8.3.2    U.K.
         8.3.3    France
         8.3.4    Italy
         8.3.5    Spain
         8.3.6    Rest-of-Europe
8.4    Asia-Pacific
         8.4.1    China
         8.4.2    India
         8.4.3    Japan
         8.4.4    Australia
         8.4.5    South Korea
         8.4.6    Singapore
         8.4.7    Rest-of-Asia-Pacific
8.5    Rest-of-the-World

9.1    Overview
9.2    CSL Limited
         9.2.1    Company Overview
         9.2.2    Role of CSL Limited in the Global Blood and Plasma Components Market
         9.2.3    Key Competitors of the Company
         9.2.4    Financials
         9.2.5    Key Insights About the Financial Health of the Company
         9.2.6    Corporate Strategies
                     9.2.6.1    Business Expansion
         9.2.7    Business Strategies
                     9.2.7.1    Product Approval
         9.2.8    SWOT Analysis
9.3    Grifols, S.A.
         9.3.1    Company Overview
         9.3.2    Role of Grifols, S.A. in the Global Blood and Plasma Components Market
         9.3.3    Key Competitors of the Company
         9.3.4    Financials
         9.3.5    Key Insights About the Financial Health of the Company
         9.3.6    Corporate Strategies
                     9.3.6.1    Mergers and Acquisitions
                     9.3.6.2    Synergistic Activities
                     9.3.6.3    Business Expansion and Funding
         9.3.7    Business Strategies
                     9.3.7.1    Product Launch
         9.3.8    SWOT Analysis
9.4    ADMA Biologics, Inc.
         9.4.1    Company Overview
         9.4.2    Role of ADMA Biologics, Inc. in the Global Blood and Plasma Components Market
         9.4.3    Key Competitors of the Company
         9.4.4    Financials
         9.4.5    Key Insights About the Financial Health of the Company
         9.4.6    Corporate Strategies
                     9.4.6.1    Synergistic Activities
         9.4.7    Business Strategies
                     9.4.7.1    Product Launches
                     9.4.7.2    Product Approvals
         9.4.8    SWOT Analysis
9.5    Takeda Pharmaceutical Company Limited
         9.5.1    Company Overview
         9.5.2    Role of Takeda Pharmaceutical Company Limited in the Global Blood and Plasma Components Market
         9.5.3    Key Competitors of the Company
         9.5.4    Financials
         9.5.5    Key Insights About the Financial Health of the Company
         9.5.6    SWOT Analysis
9.6    GC Pharma
         9.6.1    Company Overview
         9.6.2    Role of GC Pharma in the Global Blood and Plasma Components Market
         9.6.3    Key Competitors of the Company
         9.6.4    Corporate Strategies
                     9.6.4.1    Synergistic Activities
                     9.6.4.2    Business Expansion
         9.6.5    SWOT Analysis
9.7    Octapharma AG
         9.7.1    Company Overview
         9.7.2    Role of Octapharma AG in the Global Blood and Plasma Components Market
         9.7.3    Key Competitors of the Company
         9.7.4    Financials
         9.7.5    Key Insights About the Financial Health of the Company
         9.7.6    Business Strategies
                     9.7.6.1    Product Approval
         9.7.7    SWOT Analysis
9.8    Kedrion S.p.A
         9.8.1    Company Overview
         9.8.2    Role of Kedrion S.p.A in the Global Blood and Plasma Components Market
         9.8.3    Key Competitors of the Company
         9.8.4    Financials
         9.8.5    Key Insights About the Financial Health of the Company
         9.8.6    Corporate Strategies
                     9.8.6.1    Mergers and Acquisitions
                     9.8.6.2    Synergistic Activities
         9.8.7    Business Strategies
                     9.8.7.1    Product Approval
         9.8.8    SWOT Analysis
9.9    Emergent BioSolutions Inc.
         9.9.1    Company Overview
         9.9.2    Role of Emergent BioSolutions Inc. in the Global Blood and Plasma Components Market
         9.9.3    Key Competitors of the Company
         9.9.4    Financials
         9.9.5    Key Insights About the Financial Health of the Company
         9.9.6    SWOT Analysis
9.10    Bio Products Laboratory Ltd.
           9.10.1    Company Overview
           9.10.2    Role of Bio Products Laboratory Ltd. in the Global Blood and Plasma Components Market
           9.10.3    Key Competitors of the Company
           9.10.4    Corporate Strategies
                         9.10.4.1    Synergistic Activities
           9.10.5    Business Strategies
                         9.10.5.1    Product Launch
           9.10.6    SWOT Analysis
9.11    LFB S.A.
           9.11.1    Company Overview
           9.11.2    Role of LFB S.A. in Global Blood and Plasma Components Market
           9.11.3    Key Competitors of the Company
           9.11.4    Corporate Strategies
                         9.11.4.1    Synergistic Activities
           9.11.5    SWOT Analysis
9.12    American red Cross
           9.12.1    Company Overview
           9.12.2    Role of American Red Cross in the Global Blood and Plasma Components Market
           9.12.3    Key Competitors of the Company
           9.12.4    Financials
           9.12.5    SWOT Analysis
9.13    Versiti, Inc.
           9.13.1    Company Overview
           9.13.2    Role of Versiti, Inc. in the Global Blood and Plasma Components Market
           9.13.3    Key Competitors of the Company
           9.13.4    SWOT Analysis
9.14    Blood Centers of America
           9.14.1    Company Overview
           9.14.2    Role of Blood Centers of America in the Global Blood and Plasma Components Market
           9.14.3    Key Customers of the Company
           9.14.4    Key Competitors of the Company
           9.14.5    SWOT Analysis
9.15    Carter BloodCare
           9.15.1    Company Overview
           9.15.2    Role of Carter BloodCare in the Global Blood and Plasma Components Market
           9.15.3    Key Competitors of the Company
           9.15.4    SWOT Analysis
9.16    Memorial Blood Centers
           9.16.1    Company Overview
           9.16.2    Role of Memorial Blood Centers in the Global Blood and Plasma Components Market
           9.16.3    Key Competitors of the Company
           9.16.4    SWOT Analysis

Table 1:    Differences between Neutrophils, Eosinophils, and Basophils
Table 2:    Major Events in the Use of Blood and Plasma Components
Table 3:    Likert Scale
Table 4:    Impact Analysis of Market Drivers
Table 5:    Impact Analysis of Market Restraints
Table 6:    List of Acute Adverse Reactions and Delayed Adverse Reactions
Table 7:    List of Companies Offering Intravenous Immunoglobulins (IVIGs)
Table 8:    List of Companies Offering Subcutaneous Immunoglobulins (SCIGs)
Table 9:    List of Companies Offering Intramuscular Immunoglobulins (IMIG)
Table 10:    List of Companies Offering Coagulation Factor VIII Concentrate
Table 11:    List of Companies Offering Coagulation Factor IX Concentrate
Table 12:    List of Companies Offering von Willebrand Factor
Table 13:    List of Key Competitors of CSL Limited
Table 14:    List of Key Competitors of Grifols, S.A.
Table 15:    List of Key Competitors of ADMA Biologics, Inc.
Table 16:    List of Key Competitors of Takeda Pharmaceutical Company Limited
Table 17:    List of Key Competitors of GC Pharma
Table 18:    List of Key Competitors of Octapharma AG
Table 19:    List of Key Competitors of Kedrion S.p.A
Table 20:    List of Key Competitors of Emergent BioSolutions Inc.
Table 21:    List of Key Competitors of Bio Products Laboratory Ltd.
Table 22:    List of Key Competitors of LFB S.A.
Table 23:    List of Key Competitors of American Red Cross
Table 24:    List of Key Competitors of Versiti, Inc.
Table 25:    List of Key Customers of Blood Centers of America
Table 26:    List of Key Competitors of Blood Centers of America
Table 27:    List of Key Competitors of Carter BloodCare
Table 28:    List of Key Competitors of Memorial Blood Centers

Figure 1:    Global Blood and Plasma Components Market, $Billion, 2020 and 2031
Figure 2:    Impact Analysis of Market Drivers and Market Restraints on the Global Blood and Plasma Components Market
Figure 3:    Global Blood and Plasma Components Market Segmentation
Figure 4:    Global Blood and Plasma Components Market (by Product), 2020 and 2031
Figure 5:    Global Blood and Plasma Components Market (by Application), 2020 and 2031
Figure 6:    Global Blood and Plasma Components Market (by End User), 2020 and 2031
Figure 7:    Global Blood and Plasma Components Services Market Snapshot (by Region)
Figure 8:    Global Blood and Plasma Components Market: Segmentation
Figure 9:    Global Blood and Plasma Components Market: Methodology
Figure 10:    Primary Research Methodology
Figure 11:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 12:    Top-Down Approach (Segment-Wise Analysis)
Figure 13:    Global Blood and Plasma Components Market, $Billion, 2020-2031
Figure 14:    Workflow of Biologics License Application (BLA) Process
Figure 15:    China’s Regulatory Institutions under NMPA
Figure 16:    Workflow of Drug Approval Process in Japan
Figure 17:    Schematic Representation of Blood Supply Chain
Figure 18:    Blood and Blood Components Storage Requirements
Figure 19:    Global Blood and Plasma Components Market: COVID-19 Impact Analysis
Figure 20:    Number of Patients with Bleeding Disorders, 2016-2020
Figure 21:    Comparison of Manufacturing Process of Plasma-Derived Medicinal Products and Traditional Pharmaceutical Products
Figure 22:    Share of Key Developments, January 2018-January 2022
Figure 23:    Share of Mergers and Acquisitions (by Company), January 2018-January 2022
Figure 24:    Share of Synergistic Activities (by Company), January 2018-January2022
Figure 25:    Share of Business Expansion, Funding, and Reimbursement Activities (by Company), January 2018-January 2022
Figure 26:    Share of Product Launches (by Company), January 2018-January 2022
Figure 27:    Share of Product Approvals (by Company), January 2018-January 2022
Figure 28:    Market Share Analysis of Global Blood and Plasma Components Market, by Company (2019 and 2020)
Figure 29:    Growth-Share Analysis for Global Blood and Plasma Components Market (by Company), 2020
Figure 30:    Global Blood and Plasma Components Market Segmentation (by Product)
Figure 31:    Global Blood and Plasma Components Market (by Transfusion Market), $Billion, 2020-2031
Figure 32:    Global Blood and Plasma Components Market (by Transfusion Market), 2020 and 2031
Figure 33:    Global Blood and Plasma Components Market (Packed Red Blood Cells), $Billion, 2020-2031
Figure 34:    Global Blood and Plasma Components Market (Platelet Products), $Billion, 2020-2031
Figure 35:    Components of Plasma
Figure 36:    Global Blood and Plasma Components Market (Frozen Plasma), $Billion, 2020-2031
Figure 37:    Global Blood and Plasma Components Market (by Plasma-Derived Products, $Billion, 2020-2031
Figure 38:    Global Blood and Plasma Components Market (by Plasma-Derived Products), 2020 and 2031
Figure 39:    Global Blood and Plasma Components Market (Immunoglobulins), $Billion, 2020-2031
Figure 40:    Global Blood and Plasma Components Market (by Immunoglobulins), 2020 and 2031
Figure 41:    Global Blood and Plasma Components Market (Intravenous Immunoglobulins), $Billion, 2020-2031
Figure 42:    Global Blood and Plasma Components Market (Subcutaneous Immunoglobulins), $Billion, 2020-2031
Figure 43:    Global Blood and Plasma Components Market (Other Immunoglobulins), $Billion, 2020-2031
Figure 44:    Coagulation Factor Concentrates Market Segmentation
Figure 45:    Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), $Billion, 2020-2031
Figure 46:    Global Blood and Plasma Components Market (by Coagulation Factor Concentrates), 2020 and 2031
Figure 47:    Global Blood and Plasma Components Market (Coagulation Factor VIII Concentrate), $Billion, 2020-2031
Figure 48:    Global Blood and Plasma Components Market (Coagulation Factor IX Concentrate), $Billion, 2020-2031
Figure 49:    Global Blood and Plasma Components Market (von Willebrand Factor), $Billion, 2020-2031
Figure 50:    Global Blood and Plasma Components Market (Prothrombin Complex Concentrates), $Billion, 2020-2031
Figure 51:    Global Blood and Plasma Components Market (Coagulation Factor XIII Concentrate), $Billion, 2020-2031
Figure 52:    Global Blood and Plasma Components Market (Albumins), $Billion, 2020-2031
Figure 53:    Global Blood and Plasma Components Market (Proteinase Inhibitors), $Billion, 2020-2031
Figure 54:    Global Blood and Plasma Components Market (Other Blood Derivatives), $Billion, 2020-2031
Figure 55:    Global Blood and Plasma Components Market Segmentation (by Application)
Figure 56:    Global Blood and Plasma Components Market (by Application), 2020 and 2031
Figure 57:    Global Blood and Plasma Components Market (by Hematology), $Billion, 2020-2031
Figure 58:    Global Blood and Plasma Components Market (by Hemoglobinopathy), $Billion, 2020-2031
Figure 59:    Types of Thalassemia
Figure 60:    Global Blood and Plasma Components Market (Thalassemia), $Billion, 2020-2031
Figure 61:    Common Types of Sickle Cell Disease (SCD)
Figure 62:    Global Blood and Plasma Components Market (Sickle Cell Disease), $Billion, 2020-2031
Figure 63:    Global Blood and Plasma Components Market (Platelet Refractoriness), $Billion, 2020-2031
Figure 64:    Global Blood and Plasma Components Market (Hematologic Malignancies Management), $Billion, 2020-2031
Figure 65:    Global Blood and Plasma Components Market (by Coagulopathy), $Billion, 2020-2031
Figure 66:    Types of Hemophilia
Figure 67:    Global Blood and Plasma Components Market (Hemophilia), $Billion, 2020-2031
Figure 68:    Types of Von Willebrand’s Disease (vWD)
Figure 69:    Global Blood and Plasma Components Market (von Willebrand Disease), $Billion, 2020-2031
Figure 70:    Classification of Thrombosis
Figure 71:    Global Blood and Plasma Components Market (Thrombosis), $Billion, 2020-2031
Figure 72:    Different Causes of Thrombocytopenia
Figure 73:    Global Blood and Plasma Components Market (Thrombocytopenia), $Billion, 2020-2031
Figure 74:    Global Blood and Plasma Components Market (Solid Tumor Management), $Billion, 2020-2031
Figure 75:    Global Blood and Plasma Components Market (Others), $Billion, 2020-2031
Figure 76:    Global Blood and Plasma Components Market Segmentation (by End User)
Figure 77:    Global Blood and Plasma Components Market (by End User), 2020 and 2031
Figure 78:    Global Blood and Plasma Components Market (Hospitals and Specialty Clinics), $Billion, 2020-2031
Figure 79:    Global Blood and Plasma Components Market (Research Institutions), $Billion, 2020-2031
Figure 80:    Global Blood and Plasma Components Market (Diagnostics Laboratories), $Billion, 2020-2031
Figure 81:    Global Blood and Plasma Components Market (Other End Users), $Billion, 2021-2031
Figure 82:    Global Blood and Plasma Components Services Market Snapshot (by Region)
Figure 83:    Global Blood and Plasma Components Market (by Region), 2020 and 2031
Figure 84:    North America Blood and Plasma Components Market, $Billion, 2020-2031
Figure 85:    U.S. Blood and Plasma Components Market, $Billion, 2020-2031
Figure 86:    Canada Blood and Plasma Components Market, $Billion, 2020-2031
Figure 87:    Europe Blood and Plasma Components Market, $Billion, 2020-2031
Figure 88:    Germany Blood and Plasma Components Market, $Billion, 2020-2031
Figure 89:    U.K. Blood and Plasma Components Market, $Billion, 2020-2031
Figure 90:    France Blood and Plasma Components Market, $Billion, 2020-2031
Figure 91:    Italy Blood and Plasma Components Market, $Billion, 2020-2031
Figure 92:    Spain Blood and Plasma Components Market, $Billion, 2020-2031
Figure 93:    Rest-of-Europe Blood and Plasma Components Market, $Billion, 2020-2031
Figure 94:    Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031
Figure 95:    China Blood and Plasma Components Market, $Billion, 2020-2031
Figure 96:    India Blood and Plasma Components Market, $Billion, 2020-2031
Figure 97:    Japan Blood and Plasma Components Market, $Billion, 2020-2031
Figure 98:    Australia Blood and Plasma Components Market, $Billion, 2020-2031
Figure 99:    South Korea Blood and Plasma Components Market, $Billion, 2020-2031
Figure 100:    Singapore Blood and Plasma Components Market, $Billion, 2020-2031
Figure 101:    Rest-of-Asia-Pacific Blood and Plasma Components Market, $Billion, 2020-2031
Figure 102:    Rest-of-the-World Blood and Plasma Components Market, $Billion, 2020-2031
Figure 103:    Total Number of Companies Profiled
Figure 104:    Global Blood and Plasma Components Market, Company Profile Overview
Figure 105:    CSL Limited: Product Portfolio
Figure 106:    CSL Limited: Overall Financials, $Million, 2018-2020
Figure 107:    CSL Limited: Revenue (by Segment), $Million, 2018-2020
Figure 108:    CSL Limited: Revenue (by Region), $Million, 2018-2020
Figure 109:    CSL Limited: R&D Expenditure, $Million, 2018-2020
Figure 110:    CSL Limited: SWOT Analysis
Figure 111:    Grifols, S.A.: Product Portfolio
Figure 112:    Grifols, S.A.: Overall Financials, $Million, 2018-2020
Figure 113:    Grifols, S.A.: Revenue (by Segment), $Million, 2018-2020
Figure 114:    Grifols, S.A.: Revenue (by Region), $Million, 2018-2020
Figure 115:    Grifols, S.A.: R&D Expenditure, $Million, 2018-2020
Figure 116:    Grifols, S.A.: SWOT Analysis
Figure 117:    ADMA Biologics, Inc.: Product Portfolio
Figure 118:    ADMA Biologics, Inc.: Overall Financials, $Million, 2018-2020
Figure 119:    ADMA Biologics, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 120:    ADMA Biologics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 121:    ADMA Biologics, Inc.: SWOT Analysis
Figure 122:    Takeda Pharmaceutical Company Limited: Product Portfolio
Figure 123:    Takeda Pharmaceutical Company Limited: Overall Financials, $Million, 2018-2020
Figure 124:    Takeda Pharmaceutical Company Limited: Revenue (by Region), $Million, 2018-2020
Figure 125:    Takeda Pharmaceutical Company Limited: R&D Expenditure, $Million, 2018-2020
Figure 126:    Takeda Pharmaceutical Company Limited: SWOT Analysis
Figure 127:    GC Pharma: Product Portfolio
Figure 128:    GC Pharma: SWOT Analysis
Figure 129:    Octapharma AG: Product Portfolio
Figure 130:    Octapharma AG: Overall Financials, $Million, 2018-2020
Figure 131:    Octapharma AG: R&D Expenditure, $Million, 2018-2020
Figure 132:    Octapharma AG: SWOT Analysis
Figure 133:    Product Portfolio
Figure 134:    Kedrion S.p.A: Overall Financials, $Million, 2018-2020
Figure 135:    Kedrion S.p.A: Revenue (by Region), $Million, 2018-2020
Figure 136:    Kedrion S.p.A: R&D Expenditure, $Million, 2018-2020
Figure 137:    Kedrion S.p.A.:  SWOT Analysis
Figure 138:    Emergent BioSolutions Inc.: Product Portfolio
Figure 139:    Emergent BioSolutions Inc.: Overall Financials, $Million, 2018-2020
Figure 140:    Emergent BioSolutions Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 141:    Emergent BioSolutions Inc.: Revenue (by Region), $Million, 2018-2020
Figure 142:    Emergent BioSolutions Inc.: R&D Expenditure, $Million, 2018-2020
Figure 143:    Emergent BioSolutions Inc.: SWOT Analysis
Figure 144:    Bio Products Laboratory Ltd.: Product Portfolio
Figure 145:    Bio Products Laboratory Ltd.:  SWOT Analysis
Figure 146:    LFB S.A.: Product Portfolio
Figure 147:    LFB S.A.: SWOT Analysis
Figure 148:    American Red Cross: Product Portfolio
Figure 149:    American Red Cross: Overall Financials, $Million, 2018-2020
Figure 150:    American Red Cross: SWOT Analysis
Figure 151:    Versiti, Inc.: Product Portfolio
Figure 152:    Versiti, Inc.: SWOT Analysis
Figure 153:    Blood Centers of America: Product Portfolio
Figure 154:    Blood Centers of America: SWOT Analysis
Figure 155:    Carter BloodCare: Product Portfolio
Figure 156:    Carter BloodCare: SWOT Analysis
Figure 157:    Memorial Blood Centers: Product Portfolio
Figure 158:    Memorial Blood Centers: SWOT Analysis

Market Report Coverage

Blood and Plasma Components Market

Base Year

2020

Market Size in 2021

$41.18 Billion

Forecast Period

2021-2031

Value Projection and Estimation by 2031

$66.47 Billion

CAGR During Forecast Period

4.90%

Number of Tables

28

Number of Pages

228

Number of Figures

158

Market Segmentation

•    Product - Transfusion Products and Plasma-Derived Products

•    Application - Hemtology, Solid Tumor Management, and Others

•    End User - Hospitals and Specialty Clinics, Research Institutions, Diagnostics Laboratories, and Other End Users

Regional Segmentation

•    North America - U.S. and Canada

•    Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe

•    Asia-Pacific - China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

•    Rest-of-the-World

Market Growth Drivers

•    Global Increase in Patients with Blood Disorders

•    Increase in Trauma Patients and Chronic Illnesses

•    Rise in Number of Product Launches and Approval

Market Challenges

•    Risk of Transfusion Transmitted Infectious Diseases and Adverse Reaction Associated with Blood Transfusion

•    Long Duration of Manufacturing Process and Strict Regulatory Guidelines

Market Opportunities

•    Increase in Adoption of Business Expansion Strategies in the Market

Key Companies Profiled

CSL Limited, Grifols, S.A., ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, GC Pharma, Octapharma AG,  Kedrion S.p.A, Emergent BioSolutions Inc., Bio Products Laboratory Ltd., LFB S.A., American Red Cross, Versiti, Inc., Blood Centers of America, Carter BloodCare, Memorial Blood Centers

Key Questions Answered in this Report:

•    How are blood and plasma components revolutionizing the hematology and solid tumor management landscape?
•    What are the major market drivers, challenges, and opportunities in the global blood and plasma components market?
•    What are the underlying structures resulting in the emerging trends within the global blood and plasma components market?
•    How did the COVID-19 pandemic impact the global blood and plasma components ecosystem?
•    What are the key development strategies that are being implemented by major players in order to sustain themselves in the competitive market?
•    What are the key regulatory implications in developed and developing regions pertaining to the use of blood and plasma components?
•    What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region in the market? 
•    What will be the growth rate of the global blood and plasma components market during the forecast period?
•    How is each segment of the market expected to grow during the forecast period 2021-2031, and what revenue is anticipated to be generated by each of the segments? Following are the segments:
        o    Product (Transfusion Market and Plasma-Derived Products)
        o    Application (Hematology, Solid Tumor Management, and Others)
        o    End Users (Hospitals and Specialty Clinics, Research Institutions, Diagnostics Laboratories, and Other End Users)
        o    Region (North America, Europe, Asia-Pacific, and Rest-of-the-World)
•    What are the growth opportunities for the blood and plasma components companies in the region of their operation?
•    Who are the leading players with significant offerings in the global blood and plasma components market? 
•    Which companies are anticipated to be highly disruptive in the future, and why?

Report Summary

Market Overview

The global blood and plasma components market is expected to witness minimal growth, attributing to the rising burden of primary immunodeficiency diseases such as hemophilia A, von Willebrand disease (vWD), and secondary immunodeficiency diseases. Further, the increasing burden of cancer, hematologic malignancies, and organ transplantation is also contributing to the growth of the market. An increase in research and development into the use of plasma components for the treatment of neurological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP) is also promoting the growth of the market. Moreover, initiatives taken by the major players in the global blood and plasma components market to expand and launch more blood and plasma collection centers across the world in order to fulfill the supply of blood and plasma components are the major factors that are expected to fuel the growth of the market. The market size in 2020 was $39.58 billion and is expected to reach $66.47 billion in 2031, growing at a CAGR of 4.90% over the forecast period 2021-2031.

Blood and Plasma Components Market

Competitive Landscape

The global blood and plasma components market comprises well-established companies as well as a few newly emerging companies. Several companies in the global blood and plasma components market are attempting to expand their presence in the market by undertaking business expansion activities such as launching new blood and plasma collection centers at new locations. Moreover, the companies are constantly working on research and development to expand the indications of already present plasma-derived products in the market. The key market players of the global blood and plasma components market witnessed majorly business expansion, product approvals, and synergistic activities in the market over the period January 2018-January 2022. The inclination of companies toward product approvals, synergistic activities, and business expansion activities suggests that companies are constantly working to explore the potential of blood and plasma components for new areas of applications and offer products to fulfill the increased demand for blood and plasma components.

Blood and Plasma Components Market - A Global and Regional Analysis

Focus on Product, Application, End User and Region - Analysis and Forecast, 2021-2031